Autor/a:
|
Montaner Tarbes, Sergio; Novell, Elena; Tarancón, Vicens; Borràs, Francesc E.; Montoya, Maria; Fraile, Lorenzo; Portillo Obando, Hernando A. del
|
Abstract:
|
The Porcine Reproductive and Respiratory Syndrome Virus
(PRRSV) is the etiological agent of one of the most important
swine diseases with a significant economic burden worldwide.
Unfortunately, available vaccines are partially effective
highlighting the need of novel approaches. Previously, antigenic
viral proteins were described in serum-derived extracellular
vesicles (EVs) from pigs previously infected with PRRSV. Here, a
targeted-pig trial was designed to determine the safety and
immunogenicity of such extracellular vesicles enriched
fractions. Our results showed that immunizations with
EV-enriched fractions from convalescence animals in combination
with montanide is safe and free of virus as immunizations with
up-to two milligrams of EV-enriched fractions did not induce
clinical symptoms, adverse effects and detectable viral
replication. In addition, this vaccine formulation was able to
elicit specific humoral IgG immune response in vaccinated
animals, albeit variably. Noticeably, sera from vaccinated
animals was diagnosed negative when tested for PRRSV using a
commercial ELISA test; thus, indicating that this new approach
differentiates vaccinated from infected animals. Lastly, after
priming animals with EV-enriched fractions from sera of
convalescence animals and boosting them with synthetic viral
peptides identified by mass spectrometry, a distinctive high and
specific IFN-\xCE\xB3 response was elicited. Altogether, our
data strongly suggest the use of serum EV-enriched fractions as
a novel vaccine strategy against PRRSV. |